DERMAVANT SCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 20th, 2018 • Dermavant Sciences LTD • Pharmaceutical preparations
This Employment Agreement (this “Agreement”) is entered into as of March 9, 2018, by and between Richard Peterson (the “Executive”) and Dermavant Sciences, Inc. (the “Company”).
AMENDED AND RESTATED SERVICES AGREEMENTAnd Restated Services Agreement • December 20th, 2018 • Dermavant Sciences LTD • Pharmaceutical preparations • New York
This Amended and Restated Services Agreement (the “Agreement”) is entered into effective as of August 20, 2018, by and among Roivant Sciences GmbH., a company with limited liability organized under the laws of Switzerland (the “Service Provider”) and Dermavant Sciences GmbH, a company with limited liability organized under the laws of Switzerland (“DSG”, and together with any Additional Service Recipient, the “Service Recipients” and each a “Service Recipient”).
RE: Separation Agreement and General ReleaseDermavant Sciences LTD • December 20th, 2018 • Pharmaceutical preparations • New York
Your employment with Dermavant Sciences, Inc. will be terminated effective September 4, 2018 (the “Termination Date”). This Separation Agreement and General Release (this “Agreement”) sets forth the terms and conditions under which Dermavant Sciences, Inc. is offering you a bonus in exchange for you making and honoring certain commitments, including agreeing not to pursue legal action against the Company as described in Sections 6 and 7.
DERMAVANT SCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 20th, 2018 • Dermavant Sciences LTD • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”) is entered into as of October 27, 2018, by and between Todd Zavodnick (the “Executive”) and Dermavant Sciences, Inc. (the “Company”).
AMENDED AND RESTATED SERVICES AGREEMENTAmended and Restated Services Agreement • December 20th, 2018 • Dermavant Sciences LTD • Pharmaceutical preparations • New York
This Amended and Restated Services Agreement (the “Agreement”) is entered into effective as of August 20, 2018, by and among Roivant Sciences, Inc., a corporation organized under the laws of the State of Delaware (the “ Service Provider”), Dermavant Sciences GmbH, a company with limited liability organized under the laws of Switzerland (“DSG”), Dermavant Sciences, Inc., a corporation organized under the laws of the State of Delaware (“DSI”), and Dermavant Sciences Ltd., an exempted limited company organized under the laws of Bermuda (“DSL”, and together with DSG and DSI, and any Additional Service Recipient the “Service Recipients” and each a “Service Recipient”).
RE: Retention AgreementRetention Agreement • December 20th, 2018 • Dermavant Sciences LTD • Pharmaceutical preparations • New York
RE: Retention AgreementRetention Agreement • December 20th, 2018 • Dermavant Sciences LTD • Pharmaceutical preparations • New York
This Retention Agreement (this “Agreement”) is being provided to you in furtherance of our prior discussions regarding your transition from the position of Chief Medical Officer (“CMO”) of Dermavant Sciences, Inc. (“ Dermavant” or the “Company”). This Agreement reflects terms discussed with you following the Company’s delivery of the Agreement to you on September 4, 2018. Consistent with such discussions, this Agreement sets forth the terms for the continuation of your employment with the Company for a transitional period extending through December 3, 2018, or such earlier date as may be determined by the Company in its sole discretion as provided for herein (such date being referred to as the “Termination Date”). Further, this Agreement sets forth the additional pay and benefits the Company is offering you in connection with your continuation of employment through the Termination Date on the terms and conditions set forth herein, and in consideration for making and honoring certain co
